Citadel Advisors’s Fusion Pharmaceuticals Inc. Common Shares FUSN Stock Holding History

Citadel Advisors’s Portfolio FUSN Stock Details FUSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-473,376	Closed	-$10.1M	–	15775
2024 Q1	$10.1M	Buy	473,376 +419,253	+775%	+$5.01M	﹤0.01%	2949
2023 Q4	$520K	Buy	+54,123	New	+$263K	﹤0.01%	8013
2023 Q1	–	Sell	-12,510	Closed	-$39.4K	–	15759
2022 Q4	$39.4K	Sell	12,510 -15,984	-56%	-$39.8K	﹤0.01%	12435
2022 Q3	$86K	Buy	+28,494	New	+$71.2K	﹤0.01%	11224
2020 Q3	–	Sell	-325,001	Closed	-$5.68M	–	10912
2020 Q2	$5.68M	Buy	+325,001	New	+$5.66M	﹤0.01%	2913

Citadel Advisors's FUSN Position: Q2 2024 in Review

Citadel Advisors sold out of Fusion Pharmaceuticals Inc. Common Shares (FUSN) in Q2 2024, closing a stake of 473,376 shares — an estimated $10.1M sold.

Citadel Advisors first reported a position in FUSN in Q2 2020 and held it in 5 quarters. The position peaked at $10.1M in Q1 2024. 0 funds tracked by Wall St. Rank hold FUSN as of Q2 2024.

Citadel Advisors reported no remaining Fusion Pharmaceuticals Inc. Common Shares position as of Q2 2024 after selling out during the quarter.
Citadel Advisors sold 473,376 Fusion Pharmaceuticals Inc. Common Shares shares in Q2 2024, an estimated $10.1M.
Citadel Advisors first reported a position in Fusion Pharmaceuticals Inc. Common Shares in Q2 2020 and held it in 5 quarters.
Citadel Advisors's Fusion Pharmaceuticals Inc. Common Shares position peaked at $10.1M in Q1 2024.
0 funds tracked by Wall St. Rank held Fusion Pharmaceuticals Inc. Common Shares as of Q2 2024.

Based on Citadel Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.